Sugi Predict

Sugi Predict / Compounds / SCHEMBL57263

SCHEMBL57263

SCHEMBL57263

CC(C)(C)OC(=O)N1CC(C(=O)O)CC(C(=O)O)C1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.54
▸ HPGD P15428 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.46
▸ MEN1 O00255 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ RECQL P46063 1/20 0.43
▸ EPHX1 P07099 1/20 0.43
▸ CHRM2 P08172 1/20 0.42
▸ CHRM1 P11229 1/20 0.42
▸ CHRM3 P20309 1/20 0.42
▸ BTK Q06187 1/20 0.41
▸ EPHX2 P34913 1/20 0.41
▸ RORC P51449 1/20 0.41
▸ GPR119 Q8TDV5 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL89062 1.00 NR1H2 (0.54) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL20220628 1.00 NR1H2 (0.54) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL7866668 0.93 NR1H2 (0.49) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL18806921 0.93 NR1H2 (0.49) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL14478714 0.93 NR1H2 (0.49) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL43159 0.92 NR1H2 (0.53) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL31460173 0.92 NR1H2 (0.48) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL13461234 0.91 NR1H2 (0.47) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL8301548 0.91 NR1H2 (0.47) NR1H2HPGDHSD17B10MEN1ALDH1A1
SCHEMBL7953060 0.91 NR1H2 (0.47) NR1H2HPGDHSD17B10MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024259246-A1 5-HT2A RECEPTOR MODULATORS AND METHODS OF USE THEREOF Transneural Therapeutics, Inc. (US) 2024-12-19 — — WO disclosed
US-20240327385-A1 SUBSTITUTED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS LIANG GUIBAI (US) 2024-10-03 — — US disclosed
WO-2020028482-A1 SMALL MOLECULES THAT SENSITIZE HIV-1 INFECTED CELLS TO ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2020-02-06 — — WO disclosed
US-20170121286-A1 METHOD FOR PRODUCING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-05-04 — — US disclosed
US-20170121286-A1 METHOD FOR PRODUCING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-05-04 — — US disclosed
EP-2527338-B1 N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL) -3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS NOVARTIS AG (CH) 2015-05-06 — — EP disclosed
EP-2181105-B1 N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL)-3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS NOVARTIS AG (CH) 2015-04-29 — — EP disclosed
US-9018374-B2 Crystal of amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-28 — — US disclosed
CN-103068816-B Crystal of amide compound TAKEDA PHARMACEUTICAL 2015-01-07 — — CN disclosed
EP-2583967-B1 CRYSTAL OF AMIDE COMPOUND TAKEDA PHARMACEUTICAL (JP) 2014-10-01 — — EP disclosed
CN-101223140-A Piperidine derivatives useful in the diagnostic and therapeutic treatment of diseases depending on renin activity NOVARTIS AG (CH) 2008-07-16 — — CN disclosed
CN-101171248-A 3-mono- and 3,5-disubstituted piperidine derivatives as renin inhibitors NOVARTIS AG (CH) 2008-04-30 — — CN disclosed
EP-1907359-A2 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS Novartis AG (CH) 2008-04-09 — — EP disclosed
EP-1879882-A1 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS Novartis AG (CH) 2008-01-23 — — EP disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 — — WO disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 — — WO disclosed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 — — WO disclosed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 — — WO disclosed
WO-2006117183-A1 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS NOVARTIS AG (CH) 2006-11-09 — — WO disclosed
WO-2006117183-A1 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS NOVARTIS AG (CH) 2006-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121286-A1 METHOD FOR PRODUCING HETEROCYCLIC COMPOUND REN, AGT, AGTR1 NR1H2 2394/4885HPGD 589/4885HSD17B10 420/4885
US-20240327385-A1 SUBSTITUTED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS REN, ACE, AGTR1 NR1H2 1257/4885HPGD 230/4885HSD17B10 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.